ReviewInternational journal of molecular sciences2024

Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs-Protocols and Advice for the FDA to Meet the ALS Act Vision.

Sarfaraz K NiaziPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.